Pahr Therapeutics Secures $14M to Advance Pulmonary Arterial Hypertension (PAH) Treatment

Pahr Therapeutics Raises Funds to Contribute to Pulmonary Arterial Hypertension

Announcement

Pahr Therapeutics Inc. was financed with $14M, along with AN Venture partners, University of Tokyo Edge Capital Partners (UTEC), and RA Capital Management. The company tends to develop therapies for pulmonary arterial hypertension (PAH). The MD/PhD RA Capital management partner, Andrew Levin, UTEC partner and board director Atsushi Usami, PhD, and AN Venture Partners Managing Partner Ken Horne have joined the board of directors in interest in this financing. Pahr and their partners’ considerate decision to learn about PAH concerns is a long-term development for many healthcare companies. Together, these partners and Pahr are creating a strong foundation for sustaining growth and strength among the regional healthcare giants.

Backbones of Pahr Therapeutics

Pahr Therapeutics was fostered at Raven, the nurturer of RA Capital Management is led by Neil Buckley, who is a venture partner at Raven. Pahr was co-founded by Drs. Makoto Okazawa, Ryotaro Asano, and Yoshikazu Nakaoka from the national cerebral and cardiovascular center (NCVC) in Osaka, Japan. The director of the vascular physiology department at NCVCX, Dr. Nakaoka, led the remarkable research in the molecular pathophysiology of PAH for decades, and his team’s research guided PAH therapeutics approaches throughout. Dr. Nakaoka was a finalist of the science2startup Japan in 2024, and worked with his mentor Andrew Levin, who helped lead the roots of Pahr Therapeutics.

These strong science leaders enabled Phar Therapeutics to accelerate its growth. The partners' contribution to this financing is a huge support to the pulmonary arterial hypertension patients. The development of new treatments will be introduced to the global healthcare market and will be further initiated in hospitals. The access to the new treatments among the vast community at the global level will be an appreciative progress to the healthcare sector. The professional healthcare providers and interns will get additional space to practice studies and learn the depth of these new therapies. The valuable financing by Pahr Therapeutics, a company that focuses on developing treatments for pulmonary arterial hypertension (PAH), will meet the needs of many PAH patients.

Views and Statements

Dr. Nakaoka said, “I am delighted to work with RA Capital management, UTEC, and AN venture partners to introduce much-needed new treatments to PAH patients. The global investors are a huge and beneficial support for our company, which inspires us and lets us make space for advancing into clinical studies. It will be visible by next year.”